New schizophrenia drug shows promise in early brain study
NCT ID NCT07626034
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests a new drug called SIPI6398 in 9 people (healthy volunteers and schizophrenia patients). Researchers use brain scans to see how much of the drug reaches brain receptors linked to schizophrenia. The goal is to find the right dose and check safety, not yet to treat symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SIPI6398 tablets
What this could lead to
If successful, this could help determine the right dose of SIPI6398 for future trials targeting schizophrenia symptoms.
What could go wrong
This is a very small, early-phase study (9 participants) focused on brain activity, not symptom improvement. It may not lead to an effective treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.